Author

S. J. Pettitt

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:DNA methylation· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:perturbation response prediction· 1 Assay:proteomics· 1

Frequent Co-Authors

C. J. Lord· 2 shared D. B. Krastev· 2 shared F. Song· 2 shared R. Brough· 2 shared A. Ashworth· 1 shared A. Drean· 1 shared A. Gulati· 1 shared A. N. J. Tutt· 1 shared

Activity by Year

2017-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. J. Lord

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells

A. Zelceski, P. Francica, L. Lingg, M. Mutlu, C. Stok, M. Liptay, J. Alexander, J. S. Baxter, R. Brough, A. Gulati, S. Haider, M. Raghunandan, F. Song, S. Sridhar, J. V. Forment, , C. J. Lord

This study shows that PSMC3IP and MND1 depletion increases PARP inhibitor sensitivity in mitotic cells through impaired D-loop formation and homology-directed repair.

bioRxiv · Aug 24, 2022Cancer Biology

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance

S. J. Pettitt, D. B. Krastev, I. Brandsma, A. Drean, F. Song, R. Aleksandrov, M. I. Harrell, M. Menon, R. Brough, J. Campbell, J. Frankum, M. Ranes, H. N. Pemberton, R. Rafiq, K. Fenwick, , C. J. Lord

The paper identifies PARP1 point mutations causing PARP inhibitor resistance through CRISPR-Cas9 screens and shows their impact on PARP1 trapping and chemotherapy sensitivity.

bioRxiv · Oct 14, 2017Cancer Biology